Please ensure Javascript is enabled for purposes of website accessibility

Why CSX, Teva Pharmaceutical Industries, and Marathon Oil Jumped Today

By Dan Caplinger - Feb 12, 2018 at 4:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Find out how these stocks led the market higher.

After last week's roller-coaster ride, investors were hoping to see a bounce, and that's exactly what they got in the form of a 400-point rise in the Dow Jones Industrials on Monday. Major benchmarks were all up around 1.5% to 1.7% in the wake of a relatively uneventful weekend and the release of information about the Trump administration's infrastructure proposal. Some stocks did even better, and CSX (CSX -0.84%), Teva Pharmaceutical Industries (TEVA 6.07%), and Marathon Oil (MRO 4.85%) were among some of the top high-profile performers on the day. Here's why they did so well.

CSX steams higher on dividend, buyback boosts

Shares of CSX rose almost 4.5% after the railroad company announced increases to its dividend and stock repurchase program. Shareholders will receive $0.22 per share in dividends on a quarterly basis beginning in March, which works out to about a 1.6% dividend yield based on share prices after the jump. CSX also announced an increase in its share repurchase program to $5 billion, which it intends to complete by the end of the first quarter of 2019. Given that the buyback is about 10% of its current market capitalization, CSX is doing a lot to return capital to shareholders at a time during which investors are still getting over the tragic death of former CEO Hunter Harrison.

CSX train going on track next to grain elevator along a colorful grass field.

Image source: CSX.

Teva gets a bounce

Teva Pharmaceutical Industries stock picked up more than 3.5%, bouncing back from extensive losses last week after the generic-drug maker reported less-than-stellar earnings late last week. The company received a positive view from analysts at Credit Suisse, which upgraded the stock from neutral to outperform and boosted its price target on the stock by 15% to $23 per share. Despite questions about its guidance for the coming year, Teva could reach its restructuring goals more quickly than many anticipate, in Credit Suisse's opinion. If Teva can overcome headwinds from generic competition and execute well in achieving its business goals, then the stock's gains today could be the beginning of a larger trend.

Marathon powers up

Finally, shares of Marathon Oil climbed 5%. The energy company's investors reacted favorably to a slight bounce in the price of crude oil, which had moved sharply lower last week. Marathon is due to announce its earnings later this week, and investors are hopeful that the company will be able to keep overcoming some of the difficulties in maintaining production that have plagued the entire industry lately. If key holdings in the Bakken shale region of North Dakota and the STACK play in Oklahoma keep doing well, then Marathon should be in good shape to keep up its winning ways regardless of whether it reinvests in new growth opportunities or uses profits to improve its balance sheet.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CSX Corporation Stock Quote
CSX Corporation
CSX
$29.32 (-0.84%) $0.25
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$8.21 (6.07%) $0.47
Marathon Oil Corporation Stock Quote
Marathon Oil Corporation
MRO
$23.12 (4.85%) $1.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.